# EPCORE NHL-1 (NCT03625037)

> First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

No report yet. It can be ordered.

- Drugs tested: epcoritamab
- Indication: relapsed or refractory B-cell non-Hodgkin lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03625037
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Genmab
- Conditions: DLBCL; High-grade B-cell Lymphoma (HGBCL); Primary Mediastinal Large B-cell Lymphoma (PMBCL); FL; MCL; Small Lymphocytic Lymphoma (SLL); Marginal Zone Lymphoma (MZL); Indolent B-cell Non-Hodgkin Lymphoma (iNHL); Aggressive B-cell Non-Hodgkin Lymphoma (aNHL)
- Interventions: Epcoritamab
- Enrollment: 666
- Primary outcome: Dose-Escalation: Dose Limiting Toxicity (DLT)
- Primary outcome: Dose-Escalation: Number of Participants with Adverse Events (AEs)
- Primary outcome: Expansion: Overall Response Rate (ORR)
- Primary outcome: Dose-OPT DLBCL, FL and MCL: Percentage of Participants with =>Grade 2 Cytokine Release Syndrome (CRS) Events and All Grade CRS Events

## Indexed commentary on EPCORE NHL-1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 10
- Podcasts: 10
- X threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=epcore-nhl-1-nct03625037

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03625037", "email": "<work email>"}; the inbox owner confirms by the emailed link.